Emerging drugs for the treatment of inflammatory bowel disease

References

• Xu F, Carlson SA, Liu Y, et al. Prevalence of inflammatory bowel disease among medicare fee-for-service beneficiaries – United States, 2001-2008. MMWR Morb Mortal Wkly Rep. 2021;70(19):698–701.
   PubMed Web of Science ®Google Scholar
• Sauer CG, Kugathasan S. Pediatric inflammatory bowel disease: highlighting pediatric differences in IBD. Gastroenterol Clin North Am. 2009 Dec;38(4):611–628.
   PubMed Web of Science ®Google Scholar
• Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008 Oct;135(4):1114–1122.
   PubMed Web of Science ®Google Scholar
• Amaro F, Chiarelli F. Growth and puberty in children with inflammatory bowel disease. Biomedicines. 2020 Oct 29;8(11):458.
   PubMed Web of Science ®Google Scholar
• Mikocka-Walus A, Knowles SR, Keefer L, et al. Controversies revisited: a systemic review of the comorbidity of depression and anxiety with inflammatory bowel disease. Inflamm Bowel Dis. 2016 Mar;22(3):752–762.
   PubMed Web of Science ®Google Scholar
• Lix LM, Graff LA, Walker JR, et al. Longitudinal study of quality of life and psychological functioning for active, fluctuating, and inactive disease patterns in inflammatory bowel disease. Inflamm Bowel Dis. 2008 Nov;14(11):1575–1584.
   PubMed Web of Science ®Google Scholar
• Bisgaard TH, Allin KH, Keefer L, et al. Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment. Nat Clin Pract Gastroenterol Hepatol. 2022;10(11):717–726.
   Google Scholar
• Beese SE, Harris IM, Dretzke J, et al. Body image dissatisfaction in patients with inflammatory bowel disease: a systemic review. BMJ Open Gastroenterol. 2019 Feb 16;6(1):e000255.
   PubMed Web of Science ®Google Scholar
• der Valk Me V, Mangen MJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalization and surgery towards anti-TNFα therapy: results from the COIN study. Gut. 2014 Jan;63(1):72–79.
   PubMed Web of Science ®Google Scholar
• Van Linschoten RCA, Visser E, Niehot CD, et al. Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents. Aliment Pharmacol Ther. 2021 Aug;54(3):234–248.
   PubMed Web of Science ®Google Scholar
• Hudesman DP, Chakravarty SD, Emond B, et al. Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study. BMC Rheumatol. 2020 Apr 2; 4(1):16.
   PubMedGoogle Scholar
• Gisbert J, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol. 2009 Mar;104(3):760–767.
   PubMed Web of Science ®Google Scholar
• Hoffmann P, Krisam J, Wehling C, et al. Ustekinumab: “Real-world” outcomes and potential predictors of nonresponse in treatment-refractory Crohn’s disease. World J Gastroenterol. 2019 Aug 21;25(31):4481–4492.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther. 2011 May;33(9):987–995.
   PubMed Web of Science ®Google Scholar
• Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency, and pharmacological aspects. J Crohns Colitis. 2010 Oct;4(4):355–366.
   PubMed Web of Science ®Google Scholar
• Singh S, Fumery M, Sandborn WJ, et al. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther. 2018 Jan;47(2):162–175.
   PubMed Web of Science ®Google Scholar
• Fumery M SS, Sandborn WJ, Sandborn WJ, et al. Systematic review review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn’s disease. Aliment Pharmacol Ther. 2018 Aug;48(4):394–409.
   PubMed Web of Science ®Google Scholar
• Sands BE, Irving PM, Hopps T, et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naïve patients with moderately to severely active Crohn’s disease: a multicenter, randomized, double-blind, parallel-group, phase 3b trial. Lancet. 2022 Jun 11;399(10342):2200–2211.
   PubMed Web of Science ®Google Scholar
• Sands BE, Peyrin-Biroulet L, EV L Jr, et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019 Sep 26;381(13):1215–1226.
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Loftus EV, Ng SC, et al. Hospitalisations and surgery in Crohn’s disease. Gut. 2012 Apr;61(4):622–629.
   PubMed Web of Science ®Google Scholar
• Singh S, Murad MH, Fumery M, et al. First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis. Clin Gastroenterol Hepatol. 2020 Sep;18(10):2179–2191.e6.
   PubMed Web of Science ®Google Scholar
• Singh S, Murad MH, Fumery M, et al. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn’s disease: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2021 Dec;6(12):1002–1014.
   PubMed Web of Science ®Google Scholar
• Bressler B, Law JK, Al Nahdi SN, et al. The use of infliximab for treatment of hospitalized patients with acute severe ulcerative colitis. Can J Gastroneterol. 2008 Nov;22(11):937–940.
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Rahier JF, Kirchgesner J. Predicting, preventing, and managing treatment-related complications in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2020 May;18(6):1324–1335.
   PubMed Web of Science ®Google Scholar
• Xie W, Xiao S, Huang H, et al. Incidence of and risk factors for paradoxical psoriasis or psoriasiform lesions in inflammatory bowel disease patients receiving anti-TNF therapy: systematic review with meta-analysis. Front Immunol. 2022 Mar 1;13:847160.
   PubMed Web of Science ®Google Scholar
• Subedi S, Gong Y, Chen Y, et al. Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events. Drug Des Devel Ther. 2019 Jul 23;13:2491–2502.
   PubMed Web of Science ®Google Scholar
• Sazonovs A, Kennedy NA, Moutsianas L, et al. HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn’s disease. Gastroenterology. 2020 Jan;158(1):189–199.
   PubMed Web of Science ®Google Scholar
• Wyant T, Leach T, Sankoh S, et al. Vedolizumab affects antibody responses to immunization selectively in the gastrointestinal tract: randomized controlled trial results. Gut. 2015 Jan;65(1):77–83.
   Google Scholar
• Milch C, Wyant T, Xu J, et al. Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype. J Neuroimmunol. 2013 Nov 15;264(1–2):123–126.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013 Aug 22;369(8):699–710.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013 Aug 22;369(8):711–721.
   PubMed Web of Science ®Google Scholar
• Ramos GP, Dimopoulos C, McDonald NM, et al. The impact of vedolizumab on pre-existing extraintestinal manifestations of inflammatory bowel disease: a multicenter study. Inflamm Bowel Dis. 2021 Jul 27;27(8):1270–1276.
   PubMed Web of Science ®Google Scholar
• Feagan B, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016 Nov 17;375(20):1946–1960.
   PubMed Web of Science ®Google Scholar
• Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019 Sep 26;381(13):1201–1214.
   PubMed Web of Science ®Google Scholar
• Deepak P, Sandborn WJ. Ustekinumab and anti-interleukin 23 agents in Crohn’s disease. Gastroenterol Clin North Am. 2017 Sep;46(3):603–626.
   PubMed Web of Science ®Google Scholar
• Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: what can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann Rheum Dis. 2018 Feb;77(2):175–187.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Panaccione R, Baert F, et al. Risankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022 May 28;399(10340):2015–2030.
   PubMed Web of Science ®Google Scholar
• Garrido-Trigo A, Salas A. Molecular structure and function of janus kinases: implications for the development of inhibitors. J Crohns Colitis. 2020 Aug 1; 14(2):S713–S724.
   PubMedGoogle Scholar
• Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017 May 4;376(18):1723–1736.
   PubMed Web of Science ®Google Scholar
• Hanauer S, Panaccione R, Danese S, et al. Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2019 Jan;17(1):139–147.
   PubMed Web of Science ®Google Scholar
• Lopez-Sanroman A, Esplugues JV, Domenech E. Pharmacology and safety of tofacitinib in ulcerative colitis. Gastroenterol Hepatol. 2021 Jan;44(1):39–48.
   PubMed Web of Science ®Google Scholar
• Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022 Jan 27;386(4):316–326.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Cohen SB. Oral surveillance and JAK inhibitor safety: the theory of relativity. Nat Rev Rheumatol. 2022 May;18(5):301–304.
   PubMed Web of Science ®Google Scholar
• Mease P, Charles-Schoeman C, Cohen S, et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann Rheum Dis. 2020;79(11):1400–1413.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Melmed GY, Vermeire S, et al. Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis. 2018 October;24(10):2258–2265.
   PubMed Web of Science ®Google Scholar
• Desai RJ, Pawar A, Khosrow-Khavar F, et al. Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study. Rheumatology (Oxford). 2021 Dec 24;61(1):121–130.
   PubMed Web of Science ®Google Scholar
• Safety trial finds risk of blood clots in the lungs and death with higher dose of tofacitinib (Xeljanz, Xeljanz XR) in rheumatoid arthritis patients; FDA to investigate. https://www.fda.gov/media/120485/download. Accessed 2022 Jun 2nd.
   Google Scholar
• Gisbert JP, Chaparro M. Safety of new biologics (vedolizumab and ustekinumab) and small molecules (tofacitinib) during pregnancy: a review. Drugs. 2020 Jul;80(11):1085–1100.
   PubMed Web of Science ®Google Scholar
• Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre double-blind, randomised trials. Lancet. 2022 Jun 4;399(10341):2113–2128.
   PubMed Web of Science ®Google Scholar
• Lasa JS, Olivera PA, Danese S, et al. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022 Feb;7(2):161–170.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Danese S, EV L Jr, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021 Jun 19;397(10292):2372–2384.
   PubMed Web of Science ®Google Scholar
• Schreiber SW, Watanabe M, Yun C, et al. OP04 safety analysis of filgotinib for ulcerative colitis: results from the phase b/3 SELECTION study and phase 2 SELECTIONLTE long-term extension study. J Crohns Colitis. 2021 May;15(1):S004–S006.
   Google Scholar
• D’Amico F, Magro F, Peyrin-Biroulet L, et al. Positioning filgotinib in the treatment algorithm of moderate to severe ulcerative colitis. J Crohns Colitis. 2022 Jun 24;16(5):835–844.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate to severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017 Jan 21;389(10066):266–275.
   PubMed Web of Science ®Google Scholar
• Scott FL, Clemons B, Brooks J, et al. Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity. Br J Pharmacol. 2016 Jun;173(11):1778–1792.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, D’Haens G, et al. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2021 Sep 30;385(14):1280–1291.
   PubMed Web of Science ®Google Scholar
• Almon E, Shaaltiel Y, Sbeit W, et al. Novel orally administered recombinant anti-TNF alpha fusion protein for the treatment of ulcerative colitis: results from a phase 2a clinical trial. J Clin Gastroenterol. 2021 Feb 1;55(2):134–140.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Baert F, Danese S, et al. Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis. Gastroenterology. 2020 Feb;158(3):562–572.e12.
   PubMed Web of Science ®Google Scholar
• Vermeire S, D’Haens G, Baert F, et al. Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn’s disease: results from the VISIBLE 2 randomised trial. J Crohns Colitis. 2022 Jan 28;16(1):27–38.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Cyrille M, Hansen MB, et al. OP035 Efficacy and safety of abrilumab (AMG 181/MEDI 7183) therapy for moderate to severe Crohn’s disease. J Crohns Colitis. Volune. 2017 February;11(1):S22–S23.
   Google Scholar
• Sandborn WJ, Cyrille M, Hansen MB, et al. Efficacy and safety of abrilumab in a randomised, placebo-controlled trial for moderate-to-severe ulcerative colitis. Gastroenteroloy. 2019 Mar;156(4):946–957.e18.
   PubMed Web of Science ®Google Scholar
• Sugiura T, Kageyama S, Andou A, et al. Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice. J Crohns Colitis. 2013 Dec;7(11):e533–42.
   PubMedGoogle Scholar
• Yoshimura N, Watanabe M, Motoya S, et al. Safety and efficacy of AJM300, an oral antagonist of α4 integrin, in induction therapy for patients with active ulcerative colitis. Gastroenterology. 2015 Dec;149(7):1775–1783.e2.
   PubMed Web of Science ®Google Scholar
• Matsuoka K, Watanabe M, Ohmori T, et al. AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis; a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Gastroenterol Hepatol. 2022 Jul;7(7):648–657.
   PubMed Web of Science ®Google Scholar
• Sands BE, Chem J, Feagan BG, et al. Efficacy and safety of MEDI2070, an antibody against interleukin23, in patients with moderate to severe Crohn’s disease: a phase 2a study. Gastroenterology. 2017 Jul;153(1):77–86.e6.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Ferrante M, Bhandari BR, et al. Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis. Gastroenterology. 2020 Feb;158(3):537–549.e10.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Kobayashi T, Morris N, et al., Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 LUCENT-1 study (ECCO abstract OP26). J Crohns Colitis. 2022;16(1): i028–i029i028–i029.
   Google Scholar
• Sands BE, Peyrin-Biroulet L, Kierkus J, et al. Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with Crohn’s disease. Gastroenterology. 2022 Feb;162(2):495–508.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, D’Haens GR, Reinisch W, et al. Guselkumab for the treatment of Crohn’s disease: induction results from the phase 2 GALAXI-1 study. Gastroenterology. 2022 May;162(6):1650–1664.e8.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Loftus JEV, et al. Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn’s disease. Gastroenterology. 2020 Jun;158(8):2123–2138.e8.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Danese S, et al. Ozanimod induction therapy for patients with moderate to severe Crohn’s disease: a single-arm, phase 2, prospective observer-blinded endpoint study. Lancet Gastroenterol Hepatol. 2020 Sep;5(9):819–828.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Peyrin-Biroulet L, Zhang J, et al. Efficacy and safety of etrasimod in a phase 2 randomised trial of patients with ulcerative colitis. Gastroenterology. 2020 Feb;158(3):550–561.
   PubMed Web of Science ®Google Scholar
• Tazi J, Begon-Pescia C, Campos N, et al. Specific and selective induction of miR-124 in immune cells by the quinolone ABX464: a transformative therapy for inflammatory diseases. Drug Discov Today. 2021 Apr;26(4):1030–1039.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Sands BE, Tilg H, et al. ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension. Lancet Gastroenterol Hepatol. 2022 Nov;7(11):1024–1035.
   PubMed Web of Science ®Google Scholar